• Trendlyne logo
  • Markets
  • Alerts
  • F&O
  • MF
  • Reports
  • Screeners
  • Subscribe
  • Superstars
  • Portfolio
  • Watchlist
  • Insider Trades
  • Results
  • Data Downloader
  • Events Calendar
  • What's New
  • Explore
  • FAQs
  • Widgets
More
    Search stocks
    IND USA
    IND
    IND
    IND
    USA
    • Stocks
    • Futures & Options
    • Mutual Funds
    • News
    • Fundamentals
    • Reports
    • Corporate Actions
    • Alerts
    • Shareholding
    logo
    Novartis India Ltd.
    14 Jul 2025
    900.15
    -0.68%
    Divi's Labs Shares Slide After Novartis' Entresto Loses Patent Lawsuit
    Divi's Labs Shares Slide After Novartis' Entresto Loses Patent Lawsuit
    NDTV Profit
    Divi's Labs makes active pharmaceutical ingredients for Entresto for Novartis, which contributes nearly 8% to Hyderabad-based drugmaker's revenue.
    Copy LinkShare onShare on Share on Share on
    Novartis India Ltd. is trading below all available SMAs
    logo
    Anthem Biosciences Ltd.
    14 Jul 2025
    848.60
    0.30%
    Anthem Biosciences issue opens today in a price band of 540-570
    Business Line
    Mobilised 1,016-cr from anchor investors on Friday
    Copy LinkShare onShare on Share on Share on
    Anthem Biosciences Ltd. has gained 48.88% in the last 1 Year
    logo
    Sigachi Industries Ltd.
    14 Jul 2025
    43.60
    -1.36%
    Sigachi's lessons: A red line on safety for pharma manufacturing units
    Business Line
    Telangana and Andhra Pradesh attempt a course correction, but is it enough?
    Copy LinkShare onShare on Share on Share on
    Sigachi Industries Ltd. has lost -20.32% in the last 3 Months
    logo
    Cipla Ltd.
    13 Jul 2025
    1571.10
    -0.30%
    Cipla To Take On Eli Lilly, Novo Nordisk With Entry Into India's Weigh-Loss Drug Sector
    Cipla To Take On Eli Lilly, Novo Nordisk With Entry Into India's Weigh-Loss Drug Sector
    NDTV Profit
    Cipla is preparing to enter the weight-loss drug making sector, heating the competition with US-based Eli Lilly & Co and Danish firm Novo Nordisk.
    Copy LinkShare onShare on Share on Share on
    Deven Choksey released a Hold report for Cipla Ltd. with a price target of 1570.0 on 08 Sep, 2025.
    Cipla gears up to enter weight management segment in India
    Business Line | 13 Jul 2025 1 more
    Cipla to enter weight management segment in India: MD & Global CEO Vohra
    Business Standard | 13 Jul 2025
    logo
    Glenmark Pharmaceuticals Ltd.
    12 Jul 2025
    2079.20
    -0.29%
    Glenmark surges 20% after major drug licensing deal with AbbVie
    Glenmark surges 20% after major drug licensing deal with AbbVie
    Economic Times
    Glenmark Pharmaceuticals shares surged following a significant licensing agreement. Ichnos Glenmark Innovation partnered with AbbVie for a drug targeting oncology and autoimmune diseases. Glenmark will receive $700 million upfront. Potential milestone payments could reach $1.2 billion. Future sales will also generate revenue for Glenmark. Analysts predict a positive re-rating of the stock due to this deal.
    Copy LinkShare onShare on Share on Share on
    Geojit BNP Paribas increased Accumulate price target of Glenmark Pharmaceuticals Ltd. to 2306.0 on 09 Sep, 2025.
    logo
    Wockhardt Ltd.
    11 Jul 2025
    1501.50
    -0.28%
    Wockhardt exits US generics biz, to focus on innovative portfolio
    Business Standard
    Wockhardt exits the US generics market after years of losses, shifting focus to new antibiotic drug discovery and biologicals, including insulin, to create long-term value.
    Copy LinkShare onShare on Share on Share on
    Wockhardt Ltd. has gained 45.42% in the last 1 Year
    Wockhardt to exit its US generics business
    Business Line | 11 Jul 2025 1 more
    Wockhardt exits US generics business, files for liquidation of subsidiaries
    Business Standard | 11 Jul 2025
    logo
    Glenmark Pharmaceuticals Ltd.
    11 Jul 2025
    2079.20
    -0.29%
    Glenmark Pharma soars 10%, hits 52-week high on cancer drug licensing deal
    Business Standard
    At 09:30 AM, Glenmark Pharma shares were trading at 2,094.40, up by 10 per cent on the National Stock Exchange.
    Copy LinkShare onShare on Share on Share on
    Geojit BNP Paribas increased Accumulate price target of Glenmark Pharmaceuticals Ltd. to 2306.0 on 09 Sep, 2025.
    Glenmark Pharma Shares Hit Life High After License Deal With AbbVie For Cancer Drug
    NDTV Profit | 11 Jul 2025 4 more
    Glenmark Share Price Live: Glenmark Pharma locked in upper circuit after its arm's mega ISB 2001 deal
    Business Line | 11 Jul 2025
    Glenmark Pharma's Mega Deal With AbbVie Has Brokerages Mixed
    NDTV Profit | 11 Jul 2025
    Glenmark subsidiary IGI inks $700-m deal on cancer drug candidate with multinational AbbVie
    Business Line | 10 Jul 2025
    Glenmark Pharma's unit, Abbvie sign global licensing deal for cancer drug
    Business Standard | 10 Jul 2025
    logo
    Mankind Pharma Ltd.
    11 Jul 2025
    2645.00
    -0.59%
    Mankind Pharma Gets Target Price Hike Why Jefferies Calls It Top Pick
    Mankind Pharma Gets Target Price Hike Why Jefferies Calls It Top Pick
    NDTV Profit
    Jefferies anticipates that the first and second quarters will be pivotal for Mankind Pharma, with India Rx growth normalising in the second half of the fiscal.
    Copy LinkShare onShare on Share on Share on
    Mankind Pharma Ltd. has an average target of 2840.50 from 2 brokers.
    Stock Market Live Updates 11 July 2025: Stock to buy today: Mankind Pharma
    Business Line | 11 Jul 2025 2 more
    Today's Stock Recommendation: July 11, 2025
    Business Line | 11 Jul 2025
    Stock to buy today: Mankind Pharma (2,543) BUY
    Business Line | 11 Jul 2025
    logo
    Shilpa Medicare Ltd.
    10 Jul 2025
    828.90
    0.47%
    Here's why Shilpa Medicare share price is buzzing in trade today; details
    Business Standard
    Shilpa Medicare shares rose today after the company secured GMP certification from Saudi Arabia's SFDA for its Unit VI facility in Dabaspet, Bengaluru.
    Copy LinkShare onShare on Share on Share on
    Shilpa Medicare Ltd. is trading above its 200 day SMA of 784.5
    logo
    Emcure Pharmaceuticals Ltd.
    10 Jul 2025
    1338.30
    -0.31%
    Emcure Pharma rises over 2% as USFDA issues Form 483 with Zero observations
    Business Standard
    Emcure Pharma share price rose in trade after the company announced that United States Food and Drug Administration (USFDA) issued Form 483 with zero observations for its Sanand, Ahmedabad unit.
    Copy LinkShare onShare on Share on Share on
    Emcure Pharmaceuticals Ltd. has gained 30.14% in the last 6 Months
    more
    loading
    Trendlyne Logo Trendlyne
    Stay ahead of the market
    Markets Today
    • Nifty 50 today
    • Sensex today
    • Latest Quarterly results
    • FII & DII data today
    Dashboard
    • Industry & Sector analysis
    • ETFs
    • Mutual Funds
    • Bullish & Bearish spread
    • Global Indices
    Tools
    • Compare stocks
    • Widgets
    • Data Downloader
    • Excel Connect
    IPOs
    • Dashboard (Mainboard & SME)
    • Upcoming IPOs
    • Recently Listed IPOs
    • Most Successful IPOs
    Upcoming IPOs
    • JD Cables
    • GK Energy
    • Siddhi Cotspin
    Quick Links
    • Contact us
    • Blogs
    • FAQs
    Company
    • Privacy
    • Terms of Use
    • Disclaimer
    Trendlyne Products
    • Starfolio
    • SmartOptions
    • Trendlyne US Global
    Get Mobile App
    • Android
    • iOS

    Copyright © 2025 Giskard Datatech Pvt Ltd